DAHON Launches "LUNDEN" Series Tri-Fold Bikes, Redefining Performance with DAHON-V Tech

CHICAGO, Feb. 10, 2026 /PRNewswire/ -- Tri-fold bikes have surged in popularity in recent years for their compact and portable design, becoming a popular choice for many casual cyclists. However, limited differentiation and uneven engineering standards across the category have led to wide variations in ride quality and performance. Although certain manufacturers of carbon frames can offer good quality at reasonable cost, many tri-fold designs still involve trade-offs, including inadequate frame stiffness, resulting in reduced performance. These limitations highlight clear opportunities for design innovation.

DAHON TECH (HKEX Stock Code: 2543.HK) addresses these limitations with the introduction of the LUNDEN series. Designed to close the gap between compact form and full-size riding performance, the LUNDEN series features DAHON-V Tech for the first time in a tri-fold design, achieving a new balance of efficiency, rigidity, and portability. By optimizing frame and fork rigidity, the LUNDEN delivers improved power transfer, confident handling, and a smoother, more responsive ride, whether folded for transport or ridden across urban, mixed-terrain, and light off-road environments.

Product Innovation: Addressing Core Design Challenges

16-Inch LUNDEN: Compact and lightweight, this model is engineered for easy folding, carrying, and short-distance maneuvering. The drivetrain is streamlined for enhanced aesthetics. The frame integrates DELTECH and Super Down Tube, enhancing structural stiffness, optimizing power transfer, and improving overall ride stability and acceleration.

20-Inch LUNDEN: The frame is completely redesigned for extreme rigidity, featuring a direct linkage between the headtube and the bottom bracket, strengthened seatstay for extra stability and speed. Equipped with 2.0 wide tires, it is well-suited to urban riding, uneven pavement, and light gravel conditions. Its size is 12% smaller than conventional 20-inch folding bikes, improving portability without compromising ride feel.

LUNDEN series features an innovative Dynamic Suspension System that allows for quick, on-the-fly damping adjustments based on road conditions, balancing pedaling efficiency with impact absorption. The multi-segment adjustable seatpost allows precise micro-adjustments in height and angle, ensuring optimal ergonomic fit and consistent comfort across a broad range of rider profiles.

Featuring DAHON-V Tech with Proven Performance

The LUNDEN 20" made its debut at the CABDA Midwest, USA event on February 4-5, garnering widespread acclaim from dealers for its exceptional performance tailored for adventurous riders. This model features DAHON-V Tech, including the patented DELTECH and an adjustable handlebar, making the Lunden tri-fold series equipped with the most essential elements for top-tier performance.

Previously featured in international media for its innovation and performance, DAHON-V Tech has established itself as a benchmark in folding bike technology. Building on this foundation, global folding bike leader DAHON today unveils its all-new LUNDEN series of tri-fold bikes, powered by the proprietary DAHON-V Tech.

Industry Perspective: Performance-Led Differentiation Gains Momentum

"DAHON's recent technical advances are prompting renewed attention to frame stiffness, drivetrain efficiency, and real-world ride performance," market analysts noted. As rider expectations continue to evolve, the tri-fold bike segment is gradually shifting away from price-driven competition toward performance and engineering-led differentiation. With DAHON-V Tech at the core of the LUNDEN series, DAHON positions itself at the forefront of this transition, making the segment's next phase one to watch.

For more information, please contact: cs@dahon.com

Learn more about LUNDEN: https://usa.dahon.com/blogs/news/dahon-cabda-recap

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

DAHON Launches "LUNDEN" Series Tri-Fold Bikes, Redefining Performance with DAHON-V Tech

DAHON Launches "LUNDEN" Series Tri-Fold Bikes, Redefining Performance with DAHON-V Tech

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.

Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.

To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).

Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.

Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.

The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.

Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.

This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.

These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.

Media Contact: 

Chi Zhang
media@westlake.edu.cn 
+86-15659837873

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform